ACM Research enters the back half of June with the most interesting tension in its story sitting squarely in the analyst suite — a stock that has surged 35% over the past month is now getting its price targets chased higher, even as the founder-CEO was selling into the rally just weeks ago.
The Street has turned sharply more constructive. Morgan Stanley's Charlie Chan raised his target to $130 from $90 on Tuesday, maintaining an Overweight rating — a 44% upward revision that came while the stock was trading around $99. Roth Capital moved a week earlier, lifting its Buy target to $125 from $100. Both moves follow a Q1 earnings print on June 10 that drove a 12.8% single-day gain, extending to an 18.3% five-day move — the kind of reaction that forces target upgrades. The consensus mean price target now sits at $94, which is actually below the current price, suggesting the broader analyst community is still catching up to a stock that has outrun most published models. The bull case centres on a $1.27 billion backlog up 34% year-over-year, driven by continued semiconductor capacity expansion in mainland China. Bears flag the flip side: that same China concentration introduces meaningful cyclical and geopolitical risk, with limited near-term visibility on tool shipments.
Positioning in the lending market gives little ammunition to either side. Borrow availability is exceptionally loose — roughly 28 shares are available to lend for every one already borrowed, a level that has expanded from a tighter reading of around 12x available in mid-May. Cost to borrow is running below 0.4%, down more than 20% on the week, the lowest it has been in the past six weeks. Short interest itself, at 4.9% of free float, has drifted only fractionally over the month, up about 6.8% in share terms but still well within a range that implies this is a modest, unconvinced short rather than a concentrated bear position. Options traders are equally sanguine: the put/call ratio at 0.28 is barely above its 20-day average of 0.27, sitting near its 52-week low of 0.22 — call activity is comfortably dominant. The combined picture is one of very light hedging pressure and no borrow squeeze in sight.
The contrast worth watching is between the clean positioning picture and the insider tape. Founder, President and CEO Hui (David) Wang sold roughly $3.3 million of stock on June 4, across multiple tranches, with the stock then trading in the mid-$80s. Senior Vice President Sotheara Cheav added further sells across June 4 and 5. The 90-day net insider figure is technically positive at around $15.2 million in value — but examining the recent_trades data, all reported trades in the window are sells, suggesting the net positive may reflect earlier-period grants or exercises. Wang remains the second-largest reported holder with 8.6% of shares, so the sales represent trimming rather than an exit — but the timing against a 35% monthly run is notable. BlackRock holds 11.6% and added modestly, with State Street also nudging position size higher, providing some institutional ballast.
Valuation multiples have moved sharply with the price. The P/E ratio has expanded nearly 18 turns over the past 30 days to 56x. Price-to-book has widened by more than 1.2x over the same period, now at 3.8x. EV/EBITDA has compressed slightly to 31x as earnings expectations have risen faster than the enterprise value, which is the constructive read. The ORTEX short score at 37 is low and stable — not a stock the model flags as under meaningful short pressure. The stock leads semiconductor equipment peers on growth metrics but trails on quality, where negative free cash flow and a low Piotroski score constrain the overall picture. On Tuesday, ACMR fell 3.9% against a sector-wide down day: LRCX dropped 9.3%, AMAT fell 8.5%, and MU shed 13.2%, so on a relative basis ACMR held up well even in the pullback.
The next scheduled event is Q2 earnings on August 5. Given the two most recent prints produced average one-day moves of roughly 10% and five-day moves above 16%, the setup into that date — particularly whether the backlog and China shipment outlook holds — is where the bull-versus-bear debate gets its next definitive test.
See the live data behind this article on ORTEX.
Open ACMR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
